Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia

Robert W. Buchanan; Robert Freedman; Daniel C. Javitt; Anissa Abi-Dargham; Jeffrey A. Lieberman

doi:10.1093/schbul/sbm083

Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia

Robert W. Buchanan
, Robert Freedman
, Daniel C. Javitt
, Anissa Abi-Dargham
, Jeffrey A. Lieberman

Psychiatry

Stony Brook University

University of Maryland, Baltimore
University of Colorado Anschutz Medical Campus
New York University
Columbia University

Research output: Contribution to journal › Review article › peer-review

164 Scopus citations

Abstract

Wayne Fenton was a major driving force behind the establishment of the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) and Treatment Units for Research on Neurocognition and Schizophrenia (TURNS) project mechanisms. These projects were designed to facilitate the development of new drugs for the treatment of cognitive impairments in people with schizophrenia. The MATRICS project identified 3 drug mechanisms of particular interest: cholinergic, dopaminergic, and glutamatergic. The TURNS project is designed to select potential cognitive-enhancing agents and evaluate their potential efficacy in the context of proof of concept or clinical efficacy trials. This article reviews the rationale for these 3 approaches and provides an update on the development of therapeutic agents, which act through one of these 3 mechanisms.

Original language	English
Pages (from-to)	1120-1130
Number of pages	11
Journal	Schizophrenia Bulletin
Volume	33
Issue number	5
DOIs	https://doi.org/10.1093/schbul/sbm083
State	Published - Sep 2007

Keywords

Cognitive impairments
Dopamine
Glutamate
Nicotinic receptors

Access to Document

10.1093/schbul/sbm083

Cite this

@article{644bf5b79edb4ed2bbeff586d7e6585e,

title = "Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia",

abstract = "Wayne Fenton was a major driving force behind the establishment of the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) and Treatment Units for Research on Neurocognition and Schizophrenia (TURNS) project mechanisms. These projects were designed to facilitate the development of new drugs for the treatment of cognitive impairments in people with schizophrenia. The MATRICS project identified 3 drug mechanisms of particular interest: cholinergic, dopaminergic, and glutamatergic. The TURNS project is designed to select potential cognitive-enhancing agents and evaluate their potential efficacy in the context of proof of concept or clinical efficacy trials. This article reviews the rationale for these 3 approaches and provides an update on the development of therapeutic agents, which act through one of these 3 mechanisms.",

keywords = "Cognitive impairments, Dopamine, Glutamate, Nicotinic receptors",

author = "Buchanan, \{Robert W.\} and Robert Freedman and Javitt, \{Daniel C.\} and Anissa Abi-Dargham and Lieberman, \{Jeffrey A.\}",

year = "2007",

month = sep,

doi = "10.1093/schbul/sbm083",

language = "English",

volume = "33",

pages = "1120--1130",

journal = "Schizophrenia Bulletin",

issn = "0586-7614",

publisher = "Oxford University Press",

number = "5",

}

TY - JOUR

T1 - Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia

AU - Buchanan, Robert W.

AU - Freedman, Robert

AU - Javitt, Daniel C.

AU - Abi-Dargham, Anissa

AU - Lieberman, Jeffrey A.

PY - 2007/9

Y1 - 2007/9

N2 - Wayne Fenton was a major driving force behind the establishment of the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) and Treatment Units for Research on Neurocognition and Schizophrenia (TURNS) project mechanisms. These projects were designed to facilitate the development of new drugs for the treatment of cognitive impairments in people with schizophrenia. The MATRICS project identified 3 drug mechanisms of particular interest: cholinergic, dopaminergic, and glutamatergic. The TURNS project is designed to select potential cognitive-enhancing agents and evaluate their potential efficacy in the context of proof of concept or clinical efficacy trials. This article reviews the rationale for these 3 approaches and provides an update on the development of therapeutic agents, which act through one of these 3 mechanisms.

AB - Wayne Fenton was a major driving force behind the establishment of the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) and Treatment Units for Research on Neurocognition and Schizophrenia (TURNS) project mechanisms. These projects were designed to facilitate the development of new drugs for the treatment of cognitive impairments in people with schizophrenia. The MATRICS project identified 3 drug mechanisms of particular interest: cholinergic, dopaminergic, and glutamatergic. The TURNS project is designed to select potential cognitive-enhancing agents and evaluate their potential efficacy in the context of proof of concept or clinical efficacy trials. This article reviews the rationale for these 3 approaches and provides an update on the development of therapeutic agents, which act through one of these 3 mechanisms.

KW - Cognitive impairments

KW - Dopamine

KW - Glutamate

KW - Nicotinic receptors

UR - https://www.scopus.com/pages/publications/34548321168

U2 - 10.1093/schbul/sbm083

DO - 10.1093/schbul/sbm083

M3 - Review article

C2 - 17641146

SN - 0586-7614

VL - 33

SP - 1120

EP - 1130

JO - Schizophrenia Bulletin

JF - Schizophrenia Bulletin

IS - 5

ER -

Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this